Roche will pay $3.70 a share for Anadys, a premium of 256% over Anadys's closing price Friday of $1.04.
Anadys is the developer of Setrobuvir, an oral drug in trials for treatment of chronic hepatitis C infections.
"This acquisition augments Roche's already strong HCV portfolio," said Jean-Jacques Garaud, global head of Roche Pharma Research and Early Development, in a statement. "Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon. Anadys' compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance."-- Written by Joseph Woelfel
>To contact the writer of this article, click here: Joseph Woelfel >To submit a news tip, send an email to: firstname.lastname@example.org.